New drug developer TaiGen Biotek (*-KY) reported a December 2025 revenue of NT$223 million, a staggering 6482.79% YoY increase. This surge was driven by a milestone payment from its Chinese partner following the marketing approval of Pixavir marboxil (TG-1000), an influenza antiviral, along with revenue from various international commercial collaborations.

2025 Commercialization Highlights:

• Pixavir marboxil: Successfully transitioned from the development phase to commercialization in China. Partner Joincare Pharmaceutical Group is currently managing the National Reimbursement Drug List (NRDL) application and online distribution channels.
• Pediatric Formulation: The Phase 3 trial for the pediatric version of TG-1000 is nearing the end of enrollment.
• Pipeline Diversification: TaiGen recently in-licensed ISM-4808, a novel treatment for anemia in chronic kidney disease, from Insilico Medicine, with Phase 1 trials currently being planned.

Chairman Huang Kuo-lung stated that these milestones have significantly strengthened the company’s financial structure, providing ample liquidity for future R&D operations.

Resource: 藥證里程碑款入帳助攻，太景*-KY2025年營收年增逾七成